Technical analysis of ProQR Therapeutics N.V. (PRQR): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10).
Price Performance
| 1 month | -13.49% |
| 3 months | -1.59% |
| Year-to-date | -7.92% |
| 1 year | -9.71% |
| 3 years | +20.78% |
| 5 years | -78.04% |
52-Week Range
| 52-week High | $3.10 |
| 52-week Low | $1.33 |
| Avg Volume (90d) | 947K |
Technical Indicators
| SMA 50 | $1.93 |
| SMA 200 | $1.78 |
| Beta | 0.09 |
| 30-day Volatility (annualised) | 58.4% |
| Price vs SMA 50 | -3.8% |
| Price vs SMA 200 | +4.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.75 | |
| 2025-11 | $2.34 | -14.9% |
| 2025-12 | $2.02 | -13.7% |
| 2026-01 | $1.62 | -19.8% |
| 2026-02 | $1.59 | -1.9% |
| 2026-03 | $1.62 | +1.9% |
| 2026-04 | $1.57 | -3.1% |
| 2026-05 | $1.58 | +0.6% |
| 2026-06 | $1.86 | +17.7% |
| 2026-07 | $1.72 | -7.5% |
| 2026-08 | $2.13 | +23.8% |
| 2026-09 | $1.86 | -12.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | $-0.08 | $66M |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $1.86 |
| Market Cap | $196M |
| Exchange | NASDAQ |
| Country | NL |
Valuation Ratios
| Price / Book | 2.09 |
| EV / EBITDA | -2.27 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.17 |
| Current Ratio | 3.49 |
| Piotroski F-Score | 0 |
| Altman Z-Score | -4.56 |